Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

There are a number of vaccine candidates under development against a small number of the most common outbreak filoviruses all employing the virus glycoprotein (GP) as the vaccine immunogen. However, antibodies induced by such GP vaccines are typically autologous and limited to the other members of the same species. In contrast, T-cell vaccines offer a possibility to design a single pan-filovirus vaccine protecting against all known and even likely existing, but as yet unencountered members of the family. Here, we used a cross-filovirus immunogen based on conserved regions of the filovirus nucleoprotein, matrix and polymerase to construct simian adenovirus- and poxvirus MVA-vectored vaccines, and in a proof-of-concept study demonstrated a protection of the BALB/c and C57BL/6J mice against high, lethal challenges with Ebola and Marburg viruses, two distant members of the family, by vaccine-elicited T cells in the absence of GP antibodies.

Original publication




Journal article


PLoS pathogens

Publication Date





National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.


T-Lymphocytes, Animals, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Filoviridae, Hemorrhagic Fever, Ebola, Viral Vaccines, Ebola Vaccines, Antibodies, Viral, Immunity, Cellular, Female, Male, Ebolavirus, Marburgvirus, Antibodies, Neutralizing, Proof of Concept Study